(Q39789745)

14 September 2017

title

Progress in the development of new drugs in Alzheimer's disease (English)

1 reference

14 September 2017

0 references

Antoine Piau

1

1 reference

14 September 2017

F Nourhashémi

2

1 reference

14 September 2017

C Hein

3

1 reference

14 September 2017

C Caillaud

4

1 reference

14 September 2017

B Vellas

5

1 reference

14 September 2017

publication date

1 January 2011

1 reference

The Journal of Nutrition, Health and Aging

14 September 2017

published in

1 reference

14 September 2017

volume

15

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

45-57

1 reference

Forecasting the global burden of Alzheimer’s disease

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Pharmacological approaches of neurofibrillary degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Vaccination Strategies for Alzheimer???s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Implication of APP secretases in notch signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Protein kinase C isozymes: memory therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Metabolism of amyloid-beta peptide and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Current status of metals as therapeutic targets in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Nanoparticle and other metal chelation therapeutics in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Alzheimer's disease and cholesterol: the fat connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The involvement of lipid rafts in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Alzheimer's associated inflammation, potential drug targets and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

MARKing tau for tangles and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Dephosphorylation of tau protein by calcineurin triturated into neural living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Inhibition of GSK3 dependent tau phosphorylation by metals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Involvement of oxidative stress in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Evidence of increased oxidative damage in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Oxidative damage is the earliest event in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Dietary intake of antioxidants and risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Vitamin A and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Association of vitamin E and C supplement use with cognitive function and dementia in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Dietary intake of fatty acids and fish in relation to cognitive performance at middle age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Vitamin C and Vitamin E for Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Dietary patterns and risk of dementia: the Three-City cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Lipoic acid as a novel treatment for Alzheimer's disease and related dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Role of melatonin in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Role of melatonin in Alzheimer-like neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Long-term efficacy and safety of celecoxib in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Resveratrol: a multitargeted agent for age-associated chronic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Excitatory amino acids and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

AMPA potentiator treatment of cognitive deficits in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The expanding role of BDNF: a therapeutic target for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Alzheimer's disease and neural transplantation as prospective cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Cholinesterases: roles in the brain during health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The utility of muscarinic agonists in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

M<sub>1</sub> Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

M1 receptors play a central role in modulating AD-like pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Impaired insulin secretion increases the risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Role of insulin metabolism disturbances in the development of Alzheimer disease: mini review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Intranasal insulin improves cognition and modulates beta-amyloid in early AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effects of beta-hydroxybutyrate on cognition in memory-impaired adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The menopause and HRT. HRT and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The contribution of luteinizing hormone to Alzheimer disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Gonadotropins: a cohesive gender-based etiology of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Elevated gonadotropin levels in patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The gonadotropin connection in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Testosterone supplementation improves spatial and verbal memory in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The role of aromatization in testosterone supplementation: effects on cognition in older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Growth Hormone-Releasing Hormone and Growth Hormone Secretagogues in Normal Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Glucocorticoids and the ageing hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effects of histamine H3 receptor antagonists in two models of spatial learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Homocysteine and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Folate deprivation increases presenilin expression, gamma-secretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12603-011-0012-X

NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.

21 January 2018

1 reference

12 December 2020

Memantine for dementia

1 reference

12 December 2020

Indomethacin for the treatment of Alzheimer's disease patients

1 reference

12 December 2020

Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective

1 reference

12 December 2020

Ibuprofen for Alzheimer's disease

1 reference

12 December 2020

From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease.

1 reference

12 December 2020

Inflammation and Alzheimer's disease

1 reference

12 December 2020

Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease

1 reference

12 December 2020

Metal protein attenuating compounds for the treatment of Alzheimer's disease

1 reference

12 December 2020

Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study

1 reference

12 December 2020

Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts.

1 reference

12 December 2020

Amyloid-beta metal interaction and metal chelation.

1 reference

12 December 2020

Nimodipine for primary degenerative, mixed and vascular dementia

1 reference

12 December 2020

Oxidative alterations in Alzheimer's disease

1 reference

12 December 2020

Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)

1 reference

12 December 2020

Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease?

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

MitoQ--a mitochondria-targeted antioxidant.

1 reference

12 December 2020

Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease

1 reference

12 December 2020

Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer

1 reference

12 December 2020

Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.

1 reference

12 December 2020

Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.

1 reference

12 December 2020

The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial.

1 reference

12 December 2020

Huperzine A for Alzheimer's disease

1 reference

12 December 2020

Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?

1 reference

12 December 2020

Stem cell strategies for Alzheimer's disease therapy

1 reference

12 December 2020

Mifepristone (RU 486) for Alzheimer's disease

1 reference

12 December 2020

Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid

1 reference

12 December 2020

Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease

1 reference

12 December 2020

Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia.

1 reference

12 December 2020

Research update: neurogenesis in adult brain and neuropsychiatric disorders.

1 reference

12 December 2020

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

1 reference

12 December 2020

Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

1 reference

12 December 2020

List of drugs in development for neurodegenerative diseases. Update June 2007

1 reference

12 December 2020

The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease

1 reference

12 December 2020

Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease

1 reference

12 December 2020

New directions towards safer and effective vaccines for Alzheimer's disease.

1 reference

12 December 2020

LY404187: a novel positive allosteric modulator of AMPA receptors

1 reference

12 December 2020

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.

1 reference

12 December 2020

Growth hormone releasing hormone improves the cognition of healthy older adults

1 reference

12 December 2020

The emerging role of docosahexaenoic acid in neuroinflammation.

1 reference

12 December 2020

Estrogen and Alzheimer's disease

1 reference

12 December 2020

Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine.

1 reference

12 December 2020

Vitamin E for Alzheimer's dementia and mild cognitive impairment

1 reference

12 December 2020

Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.

1 reference

12 December 2020

Coenzyme Q10: a review of its promise as a neuroprotectant.

1 reference

12 December 2020

RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization

1 reference

12 December 2020

10.1007/S12603-011-0012-X

Identifiers

DOI

1 reference

14 September 2017

1 reference